New CBUS Board member Jason O'Mara

Screen Shot 2022-01-20 at 8.49.08 am

Here's some of our history with Mr O'Mara.

Criminal racketeering charges laid against the CFMMEU and its ACT secretary

Wonder how long these will stick?

Screen Shot 2018-08-16 at 1.37.38 pm

Screen Shot 2018-08-16 at 1.31.54 pm

Criminal cartel charges laid against CFMMEU and its ACT branch secretary

16 August 2018

Criminal charges have been laid against the Construction, Forestry, Maritime, Mining and Energy Union (CFMMEU) and its ACT Divisional Branch Secretary, Jason O’Mara, in relation to alleged cartel conduct.  

“The CFMMEU and Mr O’Mara are each charged with attempting to induce suppliers of steelfixing services and scaffolding services to reach cartel contracts, arrangements or understandings containing cartel provisions in relation to services provided to builders in the ACT in 2012 to 2013,” ACCC Chair Rod Sims said.

“These charges follow a joint investigation between the ACCC and the Australian Federal Police (AFP) as part of the AFP’s role in coordinating and contributing to the Joint Police Task Force following the Royal Commission into Trade Union Governance and Corruption,” Mr Sims said.

The charges are being prosecuted by the Commonwealth Director of Public Prosecutions (CDPP). 

The first mention of the charges before the ACT Magistrates Court is scheduled for 27 September 2018.

The Competition and Consumer Act requires any trial of such offences to proceed by way of indictment in the Federal Court of Australia or a state or territory Supreme Court. 

The ACCC is unable to comment further as this is a criminal matter now before the Court.

Reporting conduct of concern in the construction industry

The ACCC has recently set up an anonymous reporting portal where members of the public can report and communicate anonymously with an ACCC investigator about anticompetitive practices in the construction sector. The portal can be accessed at www.accc.gov.au/CCUreports  

Applications for cartel immunity can be made by calling the ACCC Immunity Hotline on (02) 9230 3894 or by emailing cartelimmunity@accc.gov.au(link sends e-mail).

Notes to editors

Steelfixing services refer to the installation and fixing of reinforcement steel on building sites, including in concrete slabs. Scaffolding services include the erection and dismantling of scaffolding on building sites.

The ACCC investigates cartel conduct, manages the cartel immunity policy and process, takes civil proceedings in the Federal Court in respect of alleged cartel conduct, and refers serious cartel conduct to the CDPP for consideration for prosecution. The CDPP is responsible for prosecuting criminal cartel offences, in accordance with the Prosecution Policy of the Commonwealth. 

More general information about cartel conduct is available at Cartels

ENDS

You may recall Mr O'Mara's appearance at the Trade Union Royal Commission.


Wayne Swan FI who sent Australia into irreversible debt, takes over 700,000 people's Super.

The 'world's greatest Treasurer' (remember that?) Wayne Swan who's never had a job away from the political teat, has just got another job from the boys. 
 
Swan is now in charge of CBUS super - about $70 billion dollars of other people's money. 
 
Swan sent Australia into a debt spiral of hundreds of billions of dollars, after inheriting the Howard era's super low debt levels. 
 
The Liberals under Turnbull and Morrison have since made it even worse.
 
If you're a CBUS Super member ... you are paying this 'over achiever' about $200k a year. 
 
The good old boys always look out for the good old boys.   
 
 
 

220120 Cbus media release - Wayne Swan commences as new Cbus Chair
220120 Cbus media release - Wayne Swan commences as new Cbus Chair

Swanitch


TGA provisionally approves new Covid vaccine - Novavax

Screen Shot 2022-01-20 at 8.09.39 am

TGA provisionally approves Novavax (Biocelect Pty Ltd's) COVID-19 vaccine NUVAXOVID

20 January 2022

The Therapeutic Goods Administration (TGA) has granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) for its COVID-19 vaccine, NUVAXOVID. This is the first protein COVID-19 vaccine to receive regulatory approval in Australia.

This protein vaccine is provisionally approved and included in the Australian Register of Therapeutic Goods (ARTG) for active immunisation to prevent COVID-19 in individuals 18 years of age and older. It is recommended that the vaccine is given in 2 doses administered 3 weeks apart.

NUVAXOVID is provisionally approved for primary vaccination only. Studies for use of NUVAXOVID as a booster dose and in paediatric patients are ongoing, so the vaccine does not have regulatory approval for these purposes at this stage. The TGA will review any future application from the Sponsor as a priority.

The Novavax vaccine has received conditional marketing authorisation by the European Medicines Agency, and the World Health Organisation has issued an emergency use listing for the vaccine.

NUVAXOVID is a protein subunit vaccine. Protein vaccines use a non-infectious component found on the surface of the coronavirus and are manufactured in cells in a laboratory. After vaccination, immune cells recognise the vaccine protein as foreign and launch an immune response against it.

Provisional approval of this vaccine in Australia is subject to certain strict conditions, such as the requirement for Biocelect Pty Ltd (on behalf of Novavax Inc) to continue providing information to the TGA on longer-term efficacy and safety from ongoing clinical trials and post-market assessment.

Novavax and the Australian government announced an advance purchase agreement for 51 million doses of Novavax's COVID-19 vaccine in January 2021. The first shipment to Australia of the Novavax vaccine is expected in the coming month.

Australians can be confident that the TGA's review process of NUVAXOVID was rigorous. The decision to provisionally approve the vaccine was also informed by expert advice from the Advisory Committee on Vaccines (ACV), an independent committee with expertise in scientific, medical and clinical fields including consumer representation.


Australia approves 2 Covid-19 anti-viral drugs

Screen Shot 2022-01-20 at 8.06.30 am

The Australian Government welcomes the Therapeutic Goods Administration’s (TGA) provisional approval of the first oral treatments for COVID-19 in Australia, Lagevrio® (molnupiravir) and Paxlovid® (nirmatrelvir + ritonavir).

Lagevrio and Paxlovid are oral anti-viral treatments that have been found to be effective in treating people with mild to moderate COVID-19 who have a high risk of progressing to severe disease, reducing admissions to hospital and ICU and potential death.

The Government has secured access to 300,000 treatment courses of Merck Sharp & Dohme’s (MSD) Lagevrio® and 500,000 courses of Pfizer’s Paxlovid® for supply throughout the course of 2022, with the first deliveries of both medicines anticipated over the coming weeks. 

These oral antiviral treatments need a prescription and are taken every 12 hours for five days. They are designed to interfere with the virus’ ability to multiply.

The clinical trials of these treatments show they reduce the risk of hospitalisation or death in patients with COVID-19 who are at high risk of progressing to severe disease.  

Lagevrio and Paxlovid will supplement the existing National Medical Stockpile supplies of Xevudy (sotrovimab) and Veklury (remdesivir) and future supplies of Evusheld (tixagevimab with cilgavimab), the later pending a final TGA decision on registration. 

Xevudy is an intravenous monoclonal antibody that can also be used to treat people with mild to moderate COVID-19 who have a high risk of progressing to severe disease. It has proven effective against the omicron variant with additional supply also secured for delivery over the coming months.

Veklury is being used for the clinical care of people with moderate to severe COVID-19 symptoms who have been admitted to hospital but do not require ventilation assistance in line with the recommendations of the National COVID-19 Clinical Evidence Taskforce. 

As with other TGA approved COVID-19 treatments not everyone who contracts COVID-19 will require access to Lagevrio and Paxlovid and these treatments will be of most benefit for people most at risk of severe disease and through the oversight from a healthcare professional.

We are working to target access to those most vulnerable including the elderly and those in aged care through the National Medical Stockpile (NMS) with the view to transition to the Pharmaceutical Benefits Scheme (PBS) arrangements as supply continues to grow.

By law medicines can only be listed on the PBS following a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC).

Whilst vaccination remains the best protection against COVID-19 our Government continues work to ensure that Australians have early access to safe and effective treatments as they are approved for use by the medical experts. These agreements reinforce our strong response to managing COVID-19 outbreaks and ensures that Australia benefits from new pharmaceutical technologies.

As with all COVID-19 treatments, both of these medications have been rigorously assessed by the TGA for safety, quality and effectiveness before being provisionally registered for use in Australia.

The TGA is treating all COVID-19 treatment applications with the greatest priority as part of the Department of Health's response to the pandemic.